EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

Catherine R Armbruster iD, Yasmin K Hilliam iD, Anna C Zemke iD, Samar Atteih, Christopher W Marshall iD, John Moore, Junu Koirala, Leah Krainz, Jordan R Gaston, Stella E Lee, Vaughn S Cooper iD, Jennifer M Bomberger iD

mBio · 08.05.2024 · 15 (5)

DOI: 10.1128/mbio.00519-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 08.05.2024. Verfasst von Catherine R Armbruster und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas aeruginosa, Pseudomonas Infections, Aminophenols. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Today, more than 90% of people with cystic fibrosis (pwCF) are eligible for the highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy called elexacaftor/tezacaftor/ivacaftor (ETI) and its use is widespread. Given the drastic respiratory symptom improvement experienced by many post-ETI, clinical studies are already underway to reduce the number of respiratory therapies, including antibiotic regimens, that pwCF historically relied on to combat lung disease progression. Early studies suggest that bacterial burden in the lungs is reduced post-ETI, yet it is unknown how chronic Pseudomonas aeruginosa populations are impacted by ETI. We found that pwCF remain infected throughout their upper and lower respiratory tract with their same strain of P. aeruginosa post-ETI, and these strains continue to evolve in response to the newly CFTR-corrected airway. Our work underscores the continued importance of CF airway microbiology in the new era of highly effective CFTR modulator therapy. IMPORTANCE The highly effective cystic fibrosis transmembrane conductance regulator modulator therapy Elexakaftor/Tezacaftor/Ivacaftor (ETI) has changed cystic fibrosis (CF) disease for many people with cystic fibrosis. While respiratory symptoms are improved by ETI, we found that people with CF remain infected with Pseudomonas aeruginosa . How these persistent and evolving bacterial populations will impact the clinical manifestations of CF in the coming years remains to be seen, but the role and potentially changing face of infection in CF should not be discounted in the era of highly effective modulator therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisPseudomonas aeruginosaPseudomonas InfectionsAminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsBenzodioxolesIndolesHumansPyrazolesPyrrolesPyridinesThiophenesFemaleQuinolines

Stichwörter der Autor:innen

Pseudomonas aeruginosacystic fibrosisevolutionlung infectionpathogenesisrespiratory pathogens

Substanzen

AminophenolsQuinolonesCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsBenzodioxolesIndolesPyrazolesPyrrolesPyridineselexacaftor, ivacaftor, tezacaftor drug combination

Autor:innen und Institutionen

  • Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA.
  • Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Biological Sciences, Marquette University, Milwaukee, Wisconsin, USA.
  • Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Catherine R Armbruster, Yasmin K Hilliam, Anna C Zemke, Christopher W Marshall, Vaughn S Cooper, Jennifer M Bomberger

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • HHS | National Institutes of Health
  • Gilead Sciences
  • Cystic Fibrosis Foundation

Zitieren

APA

Armbruster, C. R., Hilliam, Y. K., Zemke, A. C., Atteih, S., Marshall, C. W., Moore, J., Koirala, J., Krainz, L., Gaston, J. R., Lee, S. E., Cooper, V. S., & Bomberger, J. M. (2024). Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. mBio, 15(5). https://doi.org/10.1128/mbio.00519-24

Vancouver

Armbruster CR, Hilliam YK, Zemke AC, Atteih S, Marshall CW, Moore J, et al. Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. mBio. 2024;15(5). doi:10.1128/mbio.00519-24

BibTeX
@article{Armbruster2024,
  author = {Armbruster, Catherine R and Hilliam, Yasmin K and Zemke, Anna C and Atteih, Samar and Marshall, Christopher W and Moore, John and Koirala, Junu and Krainz, Leah and Gaston, Jordan R and Lee, Stella E and Cooper, Vaughn S and Bomberger, Jennifer M},
  title = {Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {5},
  doi = {10.1128/mbio.00519-24}
}
Kostenlos starten →